Neothetics, a biotech targeting fat reduction with an injectable formulation of an approved asthma drug, filed on Friday with the SEC to raise up to $63 million in an initial public offering.
Business
The company has completed Phase 2 trials for LIPO-202, its lead candidate that is intended to reduce “subcutaneous fat in the central abdomen that is often characterized by people as love-handles, a pot-belly, a pouch or stomach rolls.” The drug has been well tolerated in about 800 people and the company plans to conduct two Phase 3 trials with top-line data expected by the end of 2015 for a 2H16 launch.
Help employers find you! Check out all the jobs and post your resume.
